Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Revenue | $1.4M | $922.6K | $627.3K |
| Cost of revenue | $1.0M | $821.2K | $599.0K |
| Gross profit | $355.6K | $101.3K | $28.3K |
| Gross margin | 25.5% | 11.0% | 4.5% |
| R&D | $7.3K | $2.7K | $11.4K |
| Operating income | −$3.3M | −$1.8M | −$2.2M |
| EBITDA | −$3.1M | −$1.7M | −$1.6M |
| Net income | −$3.7M | −$1.1M | −$1.6M |
| Net margin | -262.5% | -122.7% | -256.2% |
| EPS (diluted) | -0.05 | -0.01 | -0.02 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds HBOSF.
No tracked institution reports a position in HBOSF as of their last filing.
No one on the platform has traded HBOSF yet.
| $6909 |
| — |
| FPSUFCapha Pharmaceuticals Inc. | $0.00 | +0.00% | $6443 | — |
| GLSHQGelesis Holdings, Inc. | $0.00 | +0.00% | $7334 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.